HIV drug resistance and viral fitness

Advances in Pharmacology

Volumn 49, Issue , 2000, Pages 41-66

  Clavel, François ^a   Race, Esther ^a   Mammano, Fabrizio ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOGENICITY; REVIEW; VIROLOGY; VIRUS REPLICATION;

DRUG RESISTANCE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0034565934     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s1054-3589(00)49023-x     Document Type: Article

References (103)

1. D. Arion G. Borkow Z. Gu M.A. Wainberg M.A. Parniak The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase J. Biol. Chem. 271 1996 19860 19866
2. D. Arion N. Kaushik S. McCormick G. Borkow M.A. Parniak Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase Biochemistry 37 1998 15908 15917
3. N.K. Back B. Berkhout Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase Antimicrob. Agents Chemother. 41 1997 2484 2491
4. N.K. Back M. Nijhuis W. Keulen C.A. Boucher B.O. Oude Essink A.B. van Kuilenburg A.H. van Gennip B. Berkhout Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme EMBO J. 15 1996 4040 4049
5. K.A. Barrie E.E. Perez S.L. Lamers W.G. Farmerie B.M. Dunn J.W. Sleasman M.M. Goodenow Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by Human Immunodeficiency Virus type 1 Virology 219 1996 407 416
6. N. Battula L.A. Loeb On the fidelity of DNA replication: Lack of exodeoxyribo-nuclease activity and error-correcting function in avian myeloblastosis virus DNA polymerase J. Biol. Chem. 251 1976 982 986
7. K. Bebenek J. Abbotts J.D. Roberts S.H. Wilson T.A. Kunkel Specificity and mechanism of error-prone replication by human immunodeficiency virus-1 reverse transcriptase J. Biol. Chem. 264 1989 16948 16956
8. D. Boden M. Markowitz Resistance to human immunodeficiency virus type 1 protease inhibitors Antimicrob. Agents Chemother. 42 1998 2775 2783
9. A.M. Borman S. Paulous F. Clavel Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug J. Gen. Virol. 77 1996 419 426
10. C.A. Boucher N. Cammack P. Schipper R. Schuurman P. Rouse M.A. Wainberg J.M. Cameron High-level resistance to (−) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase Antimicrob. Agents Chemother. 37 1993 2231 2234
11. C.A. Boucher E. O'Sullivan J.W. Mulder C. Ramautarsing P. Kellam G. Darby J.M. Lange J. Goudsmit B.A. Larder Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects J. Infect. Dis. 165 1992 105 110
12. P.L. Boyer S.H. Hughes Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1 Antimicrob. Agents Chemother. 39 1995 1624 1628
13. A.M. Caliendo A. Savara D. An K. DeVore J.C. Kaplan R.T. D'Aquila Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication J. Virol. 70 1996 2146 2153
14. L. Carron de la Carriere S. Paulous F. Clavet F. Mammano Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity J. Virol. 73 1999 3455 3459
15. Y.K. Chow M.S. Hirsch D.P. Merrill L.J. Bechtel J.J. Eron J.C. Kaplan R.T. D'Aquila Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy Nature 361 1993 650 654
16. D.K. Clarke E.A. Duarte A. Moya S.F. Elena E. Domingo J. Holland Genetic bottlenecks and population passages cause profound fitness differences in RNA viruses J. Virol 67 1993 222 228
17. J.M. Coffin HIV population dynamics in vivo : Implications for genetic variation, pathogenesis, and therapy Science 267 1995 483 489
18. J.H. Condra D.J. Holder W.A. Schleif O.M. Blahy R.M. Danovich L.J. Gabryelski D.J. Graham D. Laird J.C. Quintero A. Rhodes H.L. Robbins E. Roth M. Shivaprakash T. Yang J.A. Chodakewitz P.J. Deutsch R.Y. Leavitt F.E. Massari J.W. Mellors K.E. Squires R.T. Steigbigel H. Teppler E.A. Emini Genetic correlates of in vivo viral resistance to indinavir, a Human Immunodeficiency Virus type 1 protease inhibitor J. Virol. 70 1996 8270 8276
19. J.H. Condra W.A. Schleif O.M. Blahy L.J. Gabryelski D.J. Graham J.C. Quintero A. Rhodes H.L. Hobbins E. Roth M. Shivaprakash D.L. Titus T. Yang H. Teppler K.E. Squires P.J. Deutsch E.A. Emini In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors Nature 374 1995 569 571
20. C. Craig E. Race J. Sheldon L. Whittaker S. Gilbert A. Moffatt J. Rose S. Dissanayeke G.W. Chirn I.B. Duncan N. Cammack HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy AIDS 12 1998 1611 1618
21. G. Croteau L. Doyon D. Thibeault G. McKercher L. Pilote D. Lamarre Impaired fitness of Human Immunodeficiency Virus type 1 variants with high-level resistance to protease inhibitors J. Virol. 71 1997 1089 1096
22. C. Debouck The HIV-1 protease as a therapeutic target for AIDS AIDS Res. Hum. Retroviruses 8 1992 153 164
23. S.G. Deeks F.M. Hecht M. Swanson T. Elbeik R. Loftus P.T. Cohen R.M. Grant HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy AIDS 13 1999 F35 F43
24. E. Domingo J.J. Holland RNA virus mutations and fitness for survival Annu. Rev. Microbiol. 51 1997 151 178
25. L. Doyon F. Poulin L. Pilote C. Clouette D. Thibeault G. Croteau D. Lamarre Second locus involved in Human Immunodeficiency Virus type 1 resistance to protease inhibitors J. Virol. 70 1996 3763 3769
26. P.S. Eastman J. Mittler R. Kelso C. Gee E. Boyer J. Kolberg M. Urdea J.M. Leonard D.W. Norbeck H. Mo M. Markowitz Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy J. Virol. 72 1998 5154 5164
27. S.P. Eastman I.B. Duncan C. Gee E. Race Acquisition of Genotypic Mutations Associated with Reduced Susceptibility to Protease Inhibitors during Saquinavir Monotherapy International Workshop on HIV Drug Resistance June, 1997, St. Petersburg, FL 1997
28. M.A. el-Farrash M.J. Kuroda T. Kitazaki T. Masuda K. Kato M. Hatanaka S. Harada Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor J. Virol. 68 1994 233 239
29. J.W. Erickson The not-so-great escape Nat. Struct. Biol. 2 1995 523 529
30. J.J. Eron Y.K. Chow A.M. Caliendo J. Videler K.M. Devote T.P. Cooley H.A. Liebman J.C. Kaplan M.S. Hirsch R.T. D'Aquila pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo Antimicrob. Agents Chemother. 37 1993 1480 1487
31. A. Faye E. Race S. Paulous E. Dam V. Obry S. Matheron M.H. Prevot V. Joly F. Clavel Can Resistance-Associated Loss of Viral Fitness Explain Discordant CD4 and Plasma HIV RNA Evolution Following Protease Inhibitor Failure? Third International Workshop on HIV Drug Resistance June, 1999, San Diego 1999
32. D. Finzi M. Hermankova T. Pierson L.M. Carruth C. Buck R.E. Chaisson T.C. Quinn K. Chadwick J. Margolick R. Brookmeyer J. Gallant M. Markowitz D.D. Ho D.D. Richman R.F. Siliciano Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy Science 278 1997 1295 1300
33. M.R. Furtado D.S. Callaway J.P. Phair K.J. Kunstman J.L. Stanton C.A. Macken A.S. Perelson S.M. Wolinsky Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy N. Engl. J. Med. 340 1999 1614 1622
34. P. Gerondelis R.H. Archer C. Palaniappan R.C. Reichman P.J. Fay R.A. Bambara L.M. Demeter The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities J. Virol. 73 1999 5803 5813
35. J. Goudsmit A. de Ronde E. de Rooij R. de Boer Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215 J. Virol. 71 1997 4479 4484
36. J. Goudsmit A. De Ronde D.D. Ho A.S. Perelson Human immunodeficiency virus fitness in vivo : Calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase J. Virol. 70 1996 5662 5664
37. R.M. Gulick J.W. Mellors D. Havlir J.J. Eron C. Gonzalez D. McMahon D.D. Richman F.T. Valentine L. Jonas A. Meibohm E.A. Emini J.A. Chodakewitz Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy N. Engl. J. Med. 337 1997 734 739
38. S.V. Gulnick L.L. Suvorov B. Liu B. Yu B. Anderson H. Mitsuya J.W. Erickson Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure Biochemistry 34 1995 9282 9287
39. S.M. Hammer K.E. Squires M.D. Hughes J.M. Grimes L.M. Demeter J.S. Currier J.J. Eron Jr J.E. Feinberg H.H. Balfour Jr L.R. Deyton J.A. Chodakewitz M.A. Fischl A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team N. Engl. J. Med. 337 1997 725 733
40. P.R. Harrigan S. Bloor B.A. Larder Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro J. Virol. 72 1998 3773 3778
41. D. Ho T. Toyoshima H. Mo D. Kempf D. Norbeck C. Chen N. Wideburg S. Burt J. Erickson M. Singh Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor J. Virol. 68 1994 2016 2020
42. D.D. Ho A.U. Neumann A.S. Perelson W. Chen J.M. Leonard M. Markowitz Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature 373 1995 123 126
43. H. Huang R. Chopra G.L. Verdine S.C. Harrison Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance Science 282 1998 1669 1675
44. A.K. Iversen R.W. Shafer K. Wehrly M.A. Winters J.L. Mullins B. Chesebro T.C. Merigan Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy J. Virol. 70 1996 1086 1090
45. A.H. Kaplan S.F. Michael R.S. Wehbie M.F. Knigge D.A. Paul L. Everitt D.J. Kempf D.W. Norbeck J.W. Erickson R. Swanstrom Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease Proc. Natl. Acad. Sci. USA 91 1994 5597 5601
46. D. Kaufmann G. Pantaleo P. Sudre A. Telenti CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART): Swiss HIV Cohort Study Lancet 351 1998 723 724
47. T.B. Kepler A.S. Perelson Drug concentration heterogeneity facilitates the evolution of drug resistance Proc. Natl. Acad. Sci. USA 95 1998 11514 11519
48. W. Keulen N.K. Back A. van Wijk C.A. Boucher B. Berkhout Initial appearance of the 184lle variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase J. Virol. 71 1997 3346 3350
49. R.M. Klabe L.T. Bacheler P.J. Ala S. Erickson-Viitanen J.L. Meek Resistance to HIV protease inhibitors: A comparison of enzyme inhibition and antiviral potency Biochemistry 37 1998 8735 8742
50. L.A. Kohlstaedt J. Wang J.M. Friedman P.A. Rice T.A. Steitz Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor Science 256 1992 1783 1790
51. B. Korber B. Foley T. Leitner F. McCutchan B. Hahn J.W. Mellors G. Myers C. Kuiken HIV-1 pol amino-acid alignments. Human Retroviruses and AIDS, a compilation and analysis of nucleic acid and amino acid sequences 1997 NIAID
52. P. Kosalaraksa M.F. Kavlick V. Maroun R. Le H. Mitsuya Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay J. Virol. 73 1999 5356 5363
53. M.J. Kuroda M.A. el-Farrash S. Choudhury S. Harada Impaired infectivity of HIV-1 after a single point mutation in the POL gene to escape the effect of a protease inhibitor in vitro Virology 210 1995 212 216
54. S.F. Lacey B.A. Larder Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance J. Virol. 68 1994 3421 3424
55. B.A. Larder S.D. Kemp Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT) Science 246 1989 1155 1158
56. B.A. Larder S. Bloor S.D. Kemp K. Hertogs R.L. Desmet V. Miller M. Sturmer S. Staszewski J. Ren D.K. Stammers D.L. Stuart R. Pauwels A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance Antimicrob. Agents Chemotber. 43 1999 1961 1967
57. B.A. Larder P. Kellam S.D. Kemp Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro Nature 365 1993 451 453
58. B.A. Larder S.D. Kemp P.R. Harrigan Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy Science 269 1995 696 699
59. W.J. Lech G. Wang Y.L. Yang Y. Chee K. Dorman D. McCrae L.C. Lazzeroni J.W. Erickson J.S. Sinsheimer A.H. Kaplan In vivo sequence diversity of the protease of human immunodeficiency virus type 1: Presence of protease inhibitor-resistant variants in untreated subject J. Virol. 70 1996 2038 2043
60. Y. Lin X. Lin L. Hong S. Foundling R.L. Heinrickson S. Thaisrivongs W. Leelamanit D. Raterman M. Shah B.M. Dunn J. Tang Effect of point mutations on the kinetics and the inhibition of Human Immunodeficiency Virus type 1 protease: Relationship to drug resistance Biochemistry 34 1995 1143 1152
61. Y. Maeda D.J. Venzon H. Mitsuya Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance J. Infect. Dis. 177 1998 1207 1213
62. F. Mammano C. Petit F. Clavel Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients J. Virol. 72 1998 7632 7637
63. M. Markowitz H. Mo D. Kempf D. Norbeck T. Bhat J. Erickson D. Ho Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor J. Virol. 69 1995 701 706
64. J. Martinez-Picado A.V. Savara L. Sutton R.T. D'Aquila Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1 J. Virol. 73 1999 3744 3752
65. A. Meyerhans R. Cheynier J. Albert M. Seth S. Kwok J. Sninsky L. Morfeldt-Manson B. Asjo S. Wain-Hobson Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations Cell 58 1989 901 910
66. M.D. Miller P.D. Lamy M.D. Fuller A.S. Mulato N.A. Margot T. Cihlar J.M. Cherrington Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity Mol. Pharmacol. 54 1998 291 297
67. A. Molla D. Kempf M. Korneyeva Q. Gao P. Shipper H. Mo M. Markowitz S. Vasavanonda T. Chernyavskyi P. Niu N. Lyons A. Hsu G. Granneman D. Ho C. Boucher J. Leonard D. Norbeck Ordered accumulation of mutations in HIV protease confers resistance to Ritonavir Nat. Med. 2 1996 760 766
68. M. Nijhuis C.A. Boucher P. Schipper T. Leitner R. Schuurman J. Albert Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy Proc. Natl. Acad. Sci. USA 95 1998 14441 144416
69. M. Nijhuis R. Schuurman D. de Jong R. van Leeuwen J. Lange S. Danner W. Keulen T. de Groot C.A. Boucher Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo J. Infect Dis. 176 1997 398 405
70. M. Nijhuis R. Schuurman P. Schipper D. de Jong T. van Bommel T. de Groot A. Molla J. Borleffs S. Danner C. Boucher Reduced replication potential of HIV-1 variants initially selected under Ritonavir therapy is restored upon selection of additional substitutions Abstracts of the International Discussion Meeting of HIV Population Dynamics, Variation and Drug Resistance Edinburgh, UK 1997
71. I.S. Novella J. Quer E. Domingo J.J. Holland Exponential fitness gains of RNA virus populations are limited by bottleneck effects J. Virol. 73 1999 1668 1671
72. M.A. Nowak S. Bonhoeffer G.M. Shaw R.M. May Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations J. Theor. Biol. 184 1997 203 217
73. M. Otto S. Garber D. Winslow C. Reid P. Aldrich P. Jadhav C. Patterson C. Hodge Y. Cheng In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease Proc. Natl. Acad. Sci. USA 90 1993 7543 7547
74. A. Patick H. Mo M. Markowitz K. Appelt B. Wu L. Musick V. Kalish S. Kaldor S. Reich D. Ho S. Webber Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease Antimicrob. Agents Chemother. 40 1996 292 297
75. A. Patick R. Rose J. Greytock C. Bechtold M. Hermsmeier P. Chen J. Barrish R. Zahler R. Colonno P. Lin Characterization of a Human Immunodeficiency Virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor J. Virol. 69 1995 2148 2152
76. A.K. Patick M. Duran Y. Cao D. Shugarts M.R. Keller E. Mazabel M. Knowles S. Chapman D.R. Kuritzkes M. Markowitz Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir Antimicrob. Agents Cbemotber. 42 1998 2637 2644
77. A.S. Perelson A.U. Neumann M. Markowitz J.M. Leonard D.D. Ho HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time Science 271 1996 1582 1586
78. C. Piketty P. Castiel L. Belec D. Batisse A. Si Mohamed J. Gilquin G. Gonzalez-Canali D. Jayle M. Karmochkine L. Weiss J.P. Aboulker M.D. Kazatchkine Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease AIDS 12 1998 745 750
79. B.D. Preston B.J. Poiesz L.A. Loeb Fidelity of HIV-1 reverse transcriptase Science 242 1988 1168 1171
80. R.M. Ribeiro S. Bonhoeffer M.A. Nowak The frequency of resistant mutant virus before antiviral therapy AIDS 12 1998 461 465
81. D.D. Richman D. Havlir J. Corbeil D. Looney C. Ignacio S.A. Spector J. Sullivan S. Cheeseman K. Barringer D. Pauletti Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy J. Virol. 68 1994 1660 1666
82. T.W. Ridky A. Kikonyogo J. Leis S. Gulnik T. Copeland J. Erickson A. Wlodawer L. Kurinov R.W. Harrison I.T. Weber Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate Biochemistry 37 1998 13835 13845
83. J.D. Roberts K. Bebenek T.A. Kunkel The accuracy of reverse transcriptase from HIV-1 Science 242 1988 1171 1173
84. N.A. Roberts Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors AIDS 9 1995 S27 S32
85. R. Rose Y. Gong J. Greytok C. Bechtold B. Terry B. Robinson M. Alam R. Colonno P. Lin Human immunodeficiency virus type 1 viral background plays a major role indevelopment of resistance to protease inhibitors Proc. Natl. Acad. Sci. USA 93 1996 1648 1653
86. V.V. Sardana A.J. Schlabach P. Graham B.L. Bush J.H. Condra J.C. Culberson L. Gotlib D.J. Graham N.E. Kohl R.L. LaFemina C.L. Schneider B.S. Wolanski J.A. Wolfgang E.A. Emini Human Immunodeficiency Virus type 1 protease inhibitors: Evaluation of resistance engendered by amino-acid substitutions in the enzyme substrate binding site Biochemistry 33 1994 2004 2010
87. R.F. Schinazi B.A. Larder J.W. Mellors Mutations in retroviral genes associated with drug resistance Int. Antiviral News 5 1997 129 137
88. P.L. Sharma C.S. Crumpacker Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation J. Virol. 71 1997 8846 8851
89. S.J. Smerdon J. Jager J. Wang L.A. Kohlstaedt A.J. Chirino J.M. Friedman P.A. Rice T.A. Steitz Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1 Proc. Natl. Acad. Sci. USA 91 1994 3911 3915
90. G. Tachedjian D.J. Hooker A.D. Gurusinghe H. Bazmi N.J. Deacon J. Mellors C. Birch J. Mills Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1 Virology 212 1995 58 68
91. G. Tachedjian J.W. Mellors H. Bazmi J. Mills Impaired fitness of foscarnet-resistant strains of human immunodeficiency virus type 1 AIDS Res. Hum. Retroviruses 14 1998 1059 1064
92. G.A. Tipples M.M. Ma K.P. Fischer V.G. Bain N.M. Kneteman D.L. Tyrrell Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo Hepatology 24 1996 714 717
93. M. Tisdale S.D. Kemp N.R. Parry B.A. Larder Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region or reverse transcriptase Proc. Natl. Acad. Sci. USA 90 1993 5653 5656
94. X. Wei S.K. Ghosh M.E. Taylor V.A. Johnson E.A. Emini P. Deutsch J.D. Lifson S. Bonhoeffer M.A. Nowak B.H. Hahn Viral dynamics in human immunodeficiency virus type 1 infection Nature 373 1995 117 122
95. D.L. Winslow S. Stack R. King H. Scarnati A. Bincsik M.J. Otto Limited sequence diversity in the HIV type 1 protease gene from clinical isolates and in vivo susceptibility to HIV protease inhibitors AIDS Res. Hum. Retroviruses 11 1995 107 113
96. M.A. Winters K.L. Colley Y.A. Girard D.J. Levee H. Hamdan R.W. Shafer D.A. Katzenstein T.C. Merigan A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors J. Clin. Invest. 102 1998 1769 1775
97. J.K. Wong M. Hezareh H.F. Gunthard D.V. Havlir C.C. Ignacio C.A. Spina D.D. Richman Recovery of replication-competent HIV despite prolonged suppression of plasma viremia Science 278 1997 1291 1295
98. J.K. Wong C.C. Ignacio F. Torriani D. Havlir N.J. Fitch D.D. Richman In vivo compartmentalization of human immunodeficiency virus: Evidence from the examination of pol sequences from autopsy tissues J. Virol. 71 1997 2059 2071
99. S. Yerly A. Rakik S.K. De Loes B. Hirschel D. Descamps F. Brun-Vezinet L. Perrin Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants J. Virol. 72 1998 3520 3523
100. E. Yuste S. Sanchez-Palomino C. Casado E. Domingo C. Lopez-Galindez Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events J. Virol. 73 1999 2745 2751
101. V. Zennou F. Mammano S. Paulous D. Mathez F. Clavel Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo J. Virol. 72 1998 3300 3306
102. L. Zhang B. Ramratnam K. Tenner-Racz Y. He M. Vesanen S. Lewin A. Talal P. Racz A.S. Perelson B.T. Korber M. Markowitz D.D. Ho Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy N. Engl. J. Med. 340 1999 1605 1613
103. Y. Zhang H. Imamichi T. Imamichi H. Lane J. Falloon M. Vasudevachari N. Salzman Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites J. Virol. 71 1997 6662 6670